Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Pancreatic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Magnetic Resonance Spectroscopy 81Specimen Handling 80Cyclophosphamide 72pembrolizumab 61Nivolumab 53Radiotherapy 52fludarabine 43Cisplatin 42Biopsy 40Carboplatin 38Standard of Care 35Dexamethasone 31Radiation 30Bevacizumab 30Rituximab 29Surveys and Questionnaires 27Radiosurgery 26Doxorubicin 26Temozolomide 25Gemcitabine 25Cytarabine 25Blood Specimen Collection 25venetoclax 24Practice Guidelines as Topic 24Paclitaxel 24fludarabine phosphate 23Ipilimumab 21atezolizumab 20Vincristine 20Interviews as Topic 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × HuMax-IL8 × 30 days × Clear all
NCT02451982 2026-06-01

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
76 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04123379 2026-05-20

Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Icahn School of Medicine at Mount Sinai

Phase 2 Completed
48 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡